Korro Bio, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

KRRO$15.73+5.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(amounts in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Revenue:
Collaboration revenue	$—	$1,090	$—	$5,100
Operating expenses:
Research and development	12,104	13,820	38,643	53,694
General and administrative	6,352	6,507	20,359	21,632
Restructuring charge	—	—	—	1,233
Total operating expenses	18,456	20,327	59,002	76,559
Loss from operations	(18,456)	(19,237)	(59,002)	(71,459)
Other income:
Other income, net	1,168	1,176	3,376	4,242
Total other income, net	1,168	1,176	3,376	4,242
Loss before provision for income taxes	(17,288)	(18,061)	(55,626)	(67,217)
Provision for income taxes	(260)	—	(463)	(1)
Net loss	$(17,548)	$(18,061)	$(56,089)	$(67,218)
Other comprehensive income:
Unrealized (loss) gain on available-for-sale marketable securities	(131)	48	(558)	(29)
Foreign currency translation adjustments, net	15	(11)	41	(25)
Comprehensive loss	$(17,664)	$(18,024)	$(56,606)	$(67,272)
Net loss per share, basic and diluted	$(0.98)	$(1.92)	$(3.57)	$(7.16)
Weighted-average shares used in computing net loss per share, basic and diluted	17,867,091	9,391,559	15,717,711	9,388,816

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.